Feature

Amid new year drug price hikes, Congress calls on manufacturers to justify costs

January 25, 2019
In 2018, after President Donald Trump publicly condemned the pharmaceutical industry for skyrocketing prescription drug prices, several of the…

FDA NewsPerspective

FDA Arthritis Advisory Committee votes in favor of Olumiant 2 mg for RA

April 23, 2018
The FDA Arthritis Advisory Committee voted 10 to 5 to recommend approval of a once-daily 2-mg dose of baricitinib for the treatment of adults with…

In the Journals

IBD, Parkinson's link suggests anti-TNF may be protective

April 23, 2018
Patients with inflammatory bowel disease showed a significantly higher risk for developing Parkinson’s disease, but early treatment with…

In the Journals

Alzheimer’s patients at no greater risk for hip fracture with long-term PPI use

March 16, 2018
The use of proton pump inhibitors over a long period did not increase the risk for hip fracture in patients with Alzheimer’s disease, according…

FDA News

FDA: PDX Aromatics recalls kratom-containing powder products for risk of Salmonella

March 12, 2018
The FDA has announced that PDX Aromatics of Portland, Oregon, has begun a recall of products containing kratom powder, an unregulated herbal…

Few older adults discuss drug interactions with others

December 29, 2017
Just 35% of older adults taking between one and five medications talked to someone about drug interactions in the past 2 years, according to findings…

In the Journals

Long-term SSRI treatment may delay progression from MCI to Alzheimer’s

November 30, 2017
Long-term selective serotonin reuptake inhibitor treatment was associated with significantly delayed progression from mild cognitive impairment to…

In the Journals

Citalopram similarly effective for depression in older, younger adults

October 10, 2017
Treatment responses to citalopram were comparable among older and younger adults with major depressive disorder, according to recent findings…

In the Journals

Methylphenidate improves apathy in mild Alzheimer’s disease

September 27, 2017
Methylphenidate significantly improved apathy, cognition, functional status, caregiver burden and depression among community-dwelling veterans with…

In the Journals

Antidepressant use in Alzheimer’s disease increases risk for head injury, TBI

August 21, 2017
Risks for head injuries and traumatic brain injuries were significantly higher among adults newly diagnosed with Alzheimer’s disease who…

Axsome launches phase 2/3 trial of AXS-05 for agitation in Alzheimer’s

July 21, 2017
Axsome Theraputics recently announced the initiation of a phase 2/3 trial assessing efficacy and safety of AXS-05, a combination of dextromethorphan…

Meeting News

Analysis shows booming Alzheimer’s disease drug development

July 19, 2017
Twenty-seven Alzheimer’s disease drugs in phase 3 clinical trials and eight drugs in phase 2 trials could launch in the next 5 years, according…

In the JournalsPerspective

Polypharmacy increases significantly during end of life

June 8, 2017
Older patients are often prescribed potentially futile drugs during their last 12 months of life, thus clinical guidelines are needed to aid…

In the Journals

Statins yielded no benefit for primary cardiovascular prevention in older adults

May 22, 2017
Among patients aged 65 years and older, there was no difference in all-cause mortality or cardiovascular outcomes between pravastatin and usual care…

Meeting News

Nearly one in four adult outpatients with CAP fail antibiotic therapy

May 21, 2017
Approximately one in four adult outpatients prescribed antibiotic therapy for community-acquired pneumonia did not adequately respond to treatment…

In the Journals

Antibiotics commonly overprescribed in elderly population

May 9, 2017
Despite clinical guidelines advising against the practice, nearly half of elderly patients presenting to a PCP for a nonbacterial acute upper…

Rexulti improves agitation in Alzheimer's disease

May 3, 2017
Findings from two phase 3 clinical trials indicated efficacy, safety and tolerability of Rexulti for agitation in individuals with Alzheimer’s…

Meeting News

Adjunctive memantine reduces agitation in Alzheimer's disease

April 24, 2017
Memantine plus cholinesterase inhibitors reduced agitation, delusion and other behavioral symptoms in individuals with Alzheimer’s disease…

In the Journals

Central nervous system polypharmacy has more than doubled over the last decade

February 14, 2017
Despite harms associated with central nervous system polypharmacy, its occurrence more than doubled from 2004 to 2013 among older adults…

FDA approves Vantrela ER for severe pain

January 18, 2017
The FDA has approved Vantrela ER, an extended release tablet, for patients with severe pain that necessitates long-term, around-the-clock treatment…